跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 3 天前AI 评分20

Clinuvel Pharmaceuticals Ltd 发布年度股东大会通知与委托书表格

6-K - Clinuvel Pharmaceuticals Ltd (0001290877) (Filer)

AI 导读

Clinuvel Pharmaceuticals Ltd 发布年度股东大会通知与委托书表格。文件于2026年10月1日提交至澳大利亚证券交易所。该文件作为6-K报告附件99.1附于美国证券交易委员会披露。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-43353

CLINUVEL PHARMACEUTICALS LIMITED

Level 22, 535 Bourke Street

Melbourne, VIC 3000

Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 
 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 1, 2026, Clinuvel Pharmaceuticals Limited filed with the Australian Securities Exchange the Company’s Notice of Annual General Meeting and Proxy Form, a copy of which is attached to this Form 6-K as Exhibit 99.1.

Exhibits

Exhibit No.   Description
     
99.1   Notice of Annual General Meeting and Proxy Form
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CLINUVEL PHARMACEUTICALS LIMITED
     
Date: October 2, 2026 By: /s/ Philippe Wolgen
  Name: Philippe Wolgen
  Title: Managing Director and Chief Executive Officer
 

来源:SEC EDGAR · 本站存档